ContraFect Corporation Stock News

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including Lysins and Amurin peptides, as new medical modal

One Stop Systems (NASDAQ:OSS) +56% reports prelim results.Genprex (NASDAQ:GNPX) +52%.Akcea Therapeutics (NASDAQ:AKCA) +14% as antisense candidate successful in mid-stage hypertriglyceridemia study.T

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 DISRUPT Trial Underway On January 10, 2020, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has be

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter Int

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors.Verona Pharma PLC (NASDAQ:VRNA) +54% on positive ensifentrine data.Mereo BioP

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal

The emergence of crowdfunding activities in the Philippines in recent years now valued to millions has compelled the Securities and Exchange Commission (SEC) to craft rules and regulations that will

Canon EOS 5D Mark III